Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 25, 2018 16:18 ET | Source: ARMO BioSciences

ARMO BioSciences Announces Poster Presentations of Pegilodecakin (AM0010) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

REDWOOD CITY, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced three abstracts on pegilodecakin (AM0010), a...
April 03, 2018 08:00 ET | Source: ARMO BioSciences

ARMO BioSciences to Participate in Panel on Cytokines at 8th Annual Cancer Immunotherapy Conference

REDWOOD CITY, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced that Martin Oft, M.D., Senior Vice President,...
April 02, 2018 08:00 ET | Source: ARMO BioSciences

ARMO BioSciences Reports FY 2017 Financial Results

First Patient Enrolled in CYPRESS 1 Trial in Non-Small Cell Lung Cancer REDWOOD CITY, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology...
March 29, 2018 08:00 ET | Source: ARMO BioSciences

ARMO BioSciences Enrolls First Patient in the CYPRESS 2 Trial Evaluating AM0010 in Non-Small Cell Lung Cancer

REDWOOD CITY, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced enrollment of its first patient in CYPRESS 2, a...
March 26, 2018 08:00 ET | Source: ARMO BioSciences

ARMO BioSciences Announces Positive Outcome of First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study

Data Monitoring Committee Recommends Study Proceed Without Modification REDWOOD CITY, Calif., March 26, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology...